Patents Examined by Bao Li
  • Patent number: 10040830
    Abstract: The present invention provides methods and compositions for protein delivery. The invention features virus like particles, methods of making virus like particles and methods of using virus like particles to deliver proteins to a cell, to provide protein therapy and to treat diseases or disorders. The invention also features methods of targeting a protein to a cell, methods of protein therapy and methods of treating diseases or disorders using a TUS protein, a NLS or NES identified from full length TUS.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: August 7, 2018
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Deb Chatterjee, Stanislaw Jan Kaczmarczyk
  • Patent number: 10039821
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: August 7, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
  • Patent number: 10035984
    Abstract: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: July 31, 2018
    Assignees: Icahn School of Medicine at Mount Sinai, Memorial Sloan-Kettering Cancer Center
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Yuman Fong
  • Patent number: 10023615
    Abstract: The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells. The present invention also relates to manufacture of said transporter cargo conjugate molecules, to a method of transporting a substance of interest (cargo) into a white blood cell and to a white blood cell comprising said transporter cargo conjugate molecules or fragments thereof.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: July 17, 2018
    Assignee: Xigen Inflammation Ltd.
    Inventor: Christophe Bonny
  • Patent number: 10000556
    Abstract: Isolated VHH monoclonal antibodies are disclosed that specifically bind to a Norovirus polypeptide. In some embodiments, the Norovirus is a Genogroup I Norovirus or a Genogroup II Norovirus. In other embodiments, the Norovirus is Norwalk or MD2004 virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. Also disclosed are methods of treating and/or preventing a NoV infection.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: June 19, 2018
    Assignees: THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept. of Health and Human Services, INSTITUTO NACIONAL DE TECHNOLOGIA AGROPECUARIA
    Inventors: Karin Bok, Lorena Laura Garaicoechea, Viviana Parreno, Andrea Pamela Aguilar, Marina Bok, Lisbeth Kim Green, Stanislav Vladimirovich Sosnovtsev
  • Patent number: 9969986
    Abstract: A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: May 15, 2018
    Assignee: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno
  • Patent number: 9952218
    Abstract: The present invention relates to an in vitro method for determining HIV neutralizing antibodies in a sample. It further relates to a fusion protein to be used in said method and a nucleic acid encoding said fusion protein.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: April 24, 2018
    Assignees: LABORATORIOS DEL DR. ESTEVE S.A., FUNDACIÓ PRIVADA INSTITUT DE RECERCA DE LA SIDA—CAIXA
    Inventors: Julián Miguel Blanco Arbués, Jorge Carrillo Molina
  • Patent number: 9952217
    Abstract: The present invention relates to a method for quantitative detection of anti-HBc and its use in monitoring disease progression of chronic hepatitis B patients and predicting therapeutic effects. By quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), it is able to monitor disease progression of chronic hepatitis B patients, effectively predict therapeutic effects in chronic hepatitis B patients who accept a therapy against hepatitis B virus (especially, a therapy based on interferon and a therapy based on nucleoside/nucleotide analog anti-HBV drug), and thus guide the patients to reasonably choose drugs.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: April 24, 2018
    Assignees: Xiamen Innovax Biotech, Co., LTD., Xiamen University
    Inventors: Quan Yuan, Liuwei Song, Wenbin Zhou, Zuxing Weng, Feihai Xu, Shengxiang Ge, Jun Zhang, Ningshao Xia
  • Patent number: 9950056
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: April 24, 2018
    Inventors: John H. Sampson, Duane A. Mitchell
  • Patent number: 9902764
    Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: February 27, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Kannan Tharakaraman
  • Patent number: 9901630
    Abstract: An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 27, 2018
    Assignee: Seqirus UK Limited
    Inventors: Giuseppe Del Giudice, Riccardo Manetti
  • Patent number: 9889194
    Abstract: Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: February 13, 2018
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Lanying Du, Yusen Zhou, Guangyu Zhao
  • Patent number: 9889169
    Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an Bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the BH3 mimetics ABT-737 and ABT-199.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: February 13, 2018
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Antonio Marchini, Junwei Li, Lea Schroeder, Jean Rommelaere, Karsten Geletneky
  • Patent number: 9890433
    Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of a human papillomavirus (HPV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: February 13, 2018
    Assignee: GEN-PROBE INCORPORATED
    Inventor: Astrid R. W. Schroder
  • Patent number: 9868778
    Abstract: The present invention provides a novel antibody capable of binding to an influenza virus. The antibody directed to the present invention consists of the amino acid sequence represented by SEQ ID NO: 15 or SEQ ID NO: 16.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 16, 2018
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventor: Jin Muraoka
  • Patent number: 9861681
    Abstract: The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: January 9, 2018
    Assignee: The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases
    Inventors: Joseph Golden, Jay Hooper
  • Patent number: 9862934
    Abstract: The present invention relates to methods for the production of biopharmaceuticals implementing a baculovirus-based system. These methods advantageously allow the production of biopharmaceuticals with a reduced number of or without contaminating baculoviral virions.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: January 9, 2018
    Assignee: GENETHON
    Inventors: Otto-Wilhelm Merten, Martin Marek, Monique Van Oers
  • Patent number: 9861691
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 9, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 9840742
    Abstract: This application relates to a DNA marker for HBV-HCC detection and the methods, kits for quantitatively measuring the amount of HBV DNA and bisulfite treated HBV DNA, and methylated HBV DNA, and the aberrant methylation of the HBV genome for the used in the chronic HBV infected populations. Detection of the presence or absence of HCC, with elevated methylation levels in the one or more regions of DNA of the mammals as compared to the level of methylation in the one or more regions of DNA in the one or more control body fluids or tissues indicating the presence of the cancer, and the absence of elevated methylation levels indicating the absence of HCC.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: December 12, 2017
    Assignee: JBS SCIENCE INC.
    Inventors: Wei Song, Surbhi Jain, Batbold Boldbaatar, Sitong Chen
  • Patent number: 9841427
    Abstract: The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 12, 2017
    Assignee: Abbott Laboratories
    Inventors: George J. Dawson, Suresh M. Desai, Robin A. Gutierrez, A. Scott Muerhoff, John Prostko, M. Felicia Bogdan, Christopher C. Marohnic